GYRE
Gyre Therapeutics Inc.
7.40$
+3.4%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 96.6% | 98.8% | 98.5% | 99.0% | 99.3% | 97.5% | 94.4% | 92.5% | 58.6% | 49.1% | 51.7% | 61.6% | |
| 50.4% | 41.9% | 26.9% | 36.6% | 25.0% | 15.6% | 32.0% | 79.7% | 29.7% | 28.8% | 9.4% | 22.3% | |
| 95.9% | 46.7% | 44.8% | 82.1% | 96.2% | 78.0% | 83.7% | 84.2% | 29.7% | 28.8% | 21.3% | 31.6% | |
| 0.1% | 0.7% | 0.1% | 0.1% | – | 15.2% | 3.5% | 3.3% | 18.4% | 14.4% | 23.2% | 22.2% | |
| -0.1% | 48.6% | 51.1% | 13.4% | – | – | 0.0% | 1.6% | 7.2% | 3.7% | 5.1% | 6.1% | |
| – | – | – | – | – | – | – | – | – | 1.3% | – | – | |
| – | – | – | – | – | – | – | 5.9% | 2.2% | 1.5% | 1.4% | 2.8% | |
| 2.6% | 54.8% | 57.8% | 22.1% | 4.0% | 30.7% | 19.8% | 26.2% | 14.8% | 88.0% | 21.5% | 14.4% | |
| 2.6% | 54.3% | 57.7% | 22.1% | 3.8% | 29.3% | 18.8% | 25.4% | 14.4% | 17.2% | 15.6% | 11.0% | |
| – | 48.5% | 50.9% | 12.9% | – | 0.5% | 0.7% | 3.6% | 0.6% | 0.2% | 0.6% | 0.4% | |
| 0.4% | 1.4% | 2.2% | 1.9% | 1.0% | 4.3% | 6.3% | 11.5% | 0.1% | 0.3% | 0.1% | 0.1% | |
| 97.4% | 45.2% | 42.2% | 77.9% | 96.0% | 69.3% | 80.2% | 73.8% | 50.2% | -13.6% | 50.5% | 63.8% | |
| -279.7% | -188.5% | -388.5% | -439.1% | -162.8% | -262.3% | -331.9% | -723.5% | 11.9% | -73.4% | -58.6% | -41.2% | |
| 0.3% | 0.4% | 2.0% | 8.7% | 9.0% | 12.2% | 20.2% | 55.0% | 89.3% | 56.5% | 81.6% | 62.1% |
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.